CRISPR Therapeutics

CRSP

Precision medicineBiotech & pharmaceuticals

$53.39vs prev close▲+2.95(+5.85%)

$44.1252W Range$75.16

30% from low

+0.61 (+1.16%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

1 buys

Concentrated buys

1M net buy

+$1.1M

≈ +21K shares

Portfolio Weight

3.19%

1M +0.07%p

Holding ETFs

2 ETFs

ARKG · ARKK

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +28.8% · Market value +30.7% · Weight +0.07%p

Trade Intensity

Minor adjustment

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.10.09	BUY	ARKG	21,487	$53.39	$1.1M
26.09.09	BUY	ARKG · ARKK	47,113	$53.45	$2.5M
26.09.08	BUY	ARKG · ARKK	110,841	$54.78	$6.1M
26.07.29	SELL	ARKK	35,272	$47.64	$1.7M
26.07.28	SELL	ARKK	108,908	$47.55	$5.2M
26.03.13	BUY	ARKG · ARKK	44,923	$48.75	$2.2M
26.03.12	BUY	ARKG · ARKK	112,815	$48.87	$5.5M
26.03.10	BUY	ARKG · ARKK	280,609	$52.80	$14.8M
26.02.20	BUY	ARKG · ARKK	20,830	$53.46	$1.1M
26.02.19	BUY	ARKG · ARKK	28,055	$54.64	$1.5M
26.02.18	BUY	ARKG · ARKK	37,075	$53.52	$2.0M
26.02.17	BUY	ARKG · ARKK	84,663	$53.17	$4.5M
26.02.13	BUY	ARKG · ARKK	5,910	$53.07	$313.6K
26.02.12	BUY	ARKG · ARKK	31,937	$48.93	$1.6M
26.01.29	BUY	ARKG · ARKK	127,184	$53.35	$6.8M

10.09BUY

21,487

ARKGClose$53.39Est. total$1.1M

09.09BUY

47,113

ARKG · ARKKClose$53.45Est. total$2.5M

09.08BUY

110,841

ARKG · ARKKClose$54.78Est. total$6.1M

07.29SELL

35,272

ARKKClose$47.64Est. total$1.7M

07.28SELL

108,908

ARKKClose$47.55Est. total$5.2M

03.13BUY

44,923

ARKG · ARKKClose$48.75Est. total$2.2M

03.12BUY

112,815

ARKG · ARKKClose$48.87Est. total$5.5M

03.10BUY

280,609

ARKG · ARKKClose$52.80Est. total$14.8M

02.20BUY

20,830

ARKG · ARKKClose$53.46Est. total$1.1M

02.19BUY

28,055

ARKG · ARKKClose$54.64Est. total$1.5M

02.18BUY

37,075

ARKG · ARKKClose$53.52Est. total$2.0M

02.17BUY

84,663

ARKG · ARKKClose$53.17Est. total$4.5M

02.13BUY

5,910

ARKG · ARKKClose$53.07Est. total$313.6K

02.12BUY

31,937

ARKG · ARKKClose$48.93Est. total$1.6M

01.29BUY

127,184

ARKG · ARKKClose$53.35Est. total$6.8M

1 / 12

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

9,625,682

Portfolio Weight

3.19%

in ETF 5.2%

Est. Value

$552M

30D Net

+$10M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$87.56

vs Current ▲ +73.6% upside

Current$50.44

Low ~ High$44.00 ~ $291.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Citizens

Market Outperform

$80.00

+58.60%

$56.98

Maintain

2026-08-31

Needham

Buy

$82.00

+62.57%

$56.98

Maintain

2026-08-31

Citizens

Market Outperform

$80.00

+58.60%

$60.90

Maintain

2026-08-25

Citigroup

Buy

$88.00

+74.46%

$53.07

Maintain

2026-08-04

HC Wainwright & Co.

Buy

$80.00

+58.60%

$59.20

Maintain

2026-07-08

1 / 4

Avg Target

$87.56

vs Current ▲ +73.6% upside

Buy

22 analysts

Strong Buy 5Buy 8Hold 9

Low $44.00

Current $50.44

High $291.00

Firm	Position	Target	Upside	Close	Action	Date
Citizens	Market Outperform	$80.00	+58.60%	$56.98	Maintain	26.08.31
Needham	Buy	$82.00	+62.57%	$56.98	Maintain	26.08.31
Citizens	Market Outperform	$80.00	+58.60%	$60.90	Maintain	26.08.25
Citigroup	Buy	$88.00	+74.46%	$53.07	Maintain	26.08.04
HC Wainwright & Co.	Buy	$80.00	+58.60%	$59.20	Maintain	26.07.08

1 / 4

Price Information

Previous Close$50.44

Open$50.82

Day Range$50.52 - $54.06

52-Week Range$44.12 - $75.16

1-Year Change-21.82%

Trading Volume

Volume1,472,147

Avg Volume (3mo)1,606,498

Valuation

Market Cap5.2B

Book Value$18.07

Shares Outstanding96,692,653

Financials

Revenue (TTM)13.4M

Net Income-451,139,008

EPS$-4.74

EBITDA-513,174,016

Profitability

P/E Ratio-

P/B Ratio2.95

Return on Equity (ROE)-26.10%

Return on Assets (ROA)-14.20%

Profit Margin0.00%

EV/EBITDA-6.98

Beta1.76

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)37.72

Company Overview

CRISPR Therapeutics AG is a gene editing company developing transformative gene-based medicines for serious diseases using its revolutionary CRISPR/Cas9 platform. Their main products include CASGEVY, a gene-edited cell therapy for hemoglobinopathies, and various CAR T cell therapies and in vivo gene editing programs for oncology, cardiovascular disease, and type 1 diabetes. The company is a leader in the field, with strategic partnerships and a portfolio targeting significant unmet medical needs.

P/B

2.95

Price-to-Book

ROE

-26.1%

Persistent loss

Beta

1.76

High volatility

RSI(14)

37.7

Neutral zone

AI-generated summary. Not investment advice.

CRISPR Therapeutics

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks